Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 vaccine (SET Technology)
- Development stage
- Preclinical
- Lead developer
- SET Technology
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
COVID-19 vaccine (SET Technology) is a DNA/RNA-based vaccine candidate currently in the optimization phase of development by SET Technology. The vaccine is designed to prevent COVID-19 by utilizing a proprietary platform to deliver genetic material encoding SARS-CoV-2 antigens, thereby stimulating the host's immune system to recognize and neutralize the virus. This candidate is part of SET Technology's broader infectious disease pipeline, which also includes vaccines for Dengue and Andes viruses.
- Other names
- SET Technology COVID-19 vaccineDNA/RNA-based COVID-19 vaccine
Beyond the preview
Go deeper on COVID-19 vaccine (SET Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 vaccine (SET Technology).